Posts

Erythropoietic Protoporphyria (EPP) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Erythropoietic protoporphyria is a genetic condition that affects heme production, which leads to the overproduction of protoporphyrin, majorly in the bone marrow. This condition leads to higher levels of the heme precursor excreted in the bile. In some cases, this disorder progresses to liver disease and eventually ends with liver transplantation. Since the bone marrow continues to produce excessive protoporphyrin after the transplant, the condition can recur in the transplanted liver. As a result, liver transplantation, while a potential treatment, tends to be a palliative measure rather than a cure due to the risk of recurrence. EPP can result from mutations of the ferrochelatase gene (FECH). Children develop pain, redness, swelling, pruritus, and a variety of hepatobiliary complications. The 5%–10% of subjects have an X-linked variant of EPP (termed XLPP) resulting from a gain-of-function mutation of the Alas2 gene.41 Mild microcytic anemia occurs in 20%–60% of patients with so
Post a Comment
Read more

Relapsed or Refractory Colorectal Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Colorectal cancer, commonly known as colon cancer, primarily arises in the colon or rectum; it is the third most prevalent form of cancer known for its slow progression over many years. Typically, it originates as a non-malignant polyp, an unusual tissue growth lining the colon. There are three main presentations of colorectal cancer: sporadic (70%), familial clustering (20%), and inherited syndrome (10%). Various risk factors are linked to the development of colon cancer, including age, environmental factors, diets high in animal fat, obesity, smoking, excessive alcohol consumption, genetic predisposition, and a history of inflammatory bowel disease. The most prevalent type of colon cancer diagnosed in patients is adenocarcinoma. Colorectal cancer development hinges on the adenoma-carcinoma sequence, characterized by a gradual accumulation of genetic alterations. In sporadic colorectal cancers, the gatekeeper pathway, governed by a gene that regulates growth, accounts for roughly
Post a Comment
Read more

FDA Clears CytoDyn’s Leronlimab for Phase II Trial in Colorectal Cancer

Image
  CytoDyn Inc., a biotechnology company specializing in the development of leronlimab, a CCR5 antagonist with potential for multiple therapeutic indications, announced today that it has received FDA clearance to commence its Phase II oncology trial. This study will evaluate the efficacy of leronlimab in patients with relapsed or refractory microsatellite stable colorectal cancer. This milestone reflects the positive development of CytoDyn’s relationship with the FDA, following productive feedback sessions and the submission of a final study protocol in September 2024. Publish Date: 04-11-2024   Source: CytoDyn Inc. Colorectal cancer, commonly known as colon cancer, primarily arises in the colon or rectum; it is the third most prevalent form of cancer known for its slow progression over many years. Typically, it originates as a non-malignant polyp, an unusual tissue growth lining the colon. There are three main presentations of colorectal cancer: sporadic (70%), familial cluste
Post a Comment
Read more